Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

p.DOM-WT1-37 DNA Vaccine

Vaccine (DNA plasmid) · Immune activation, directed at WT1

Phase 2 Most advanced trial (none active)
1 Registered trials

What is p.DOM-WT1-37 DNA Vaccine?

p.DOM-WT1-37 is a DNA vaccine encoding a fusion of tetanus toxin fragment C and the WT1.37 epitope. Upon electroporation, it induces WT1-specific cytotoxic T-lymphocyte responses against WT1-overexpressing cancer cells. It is studied in acute and chronic leukemias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (DNA plasmid)
Targets
WT1 (antigen)
Mechanism
Immune activation, directed at WT1
Pathways
T-cell activation, cytotoxic T-lymphocyte response
Therapy area
Oncology
In trials of
INO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01334060 Phase 2 Leukaemia (Acute) Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leukaemia (Acute Lymphoblastic)Leukaemia (Acute Myeloid)Leukaemia (Acute Promyelocytic)Leukaemia (Acute)Leukaemia (Chronic)

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.